journal article·2025-01-08

A Near-Infrared II Luminogen with a Photothermal Effect toward Tumor Drug Resistance Reversal

Kaihong Du, Guiquan Zhang, Dong He, Zhizai Chen, Shanyang He, Rong Hu, Anjun Qin, Ben Zhong Tang

Publisher page

Abstract

Multidrug resistance of tumor cells has greatly limited the chemotherapy effect. The development of reliable strategies to deal with tumor multidrug resistance is highly desirable for tumor therapy. In this work, a near-infrared II (NIR II) luminogen was rationally designed and prepared, which could act as a photothermal reagent to reverse the drug resistance of tumor cells by reducing the related protein expression, achieving a high inhibition efficiency with the synergistic effect of chemotherapeutic drugs. By the selection of a strong electron-withdrawing unit, the emission peak of the luminogen could reach 973 nm. Moreover, this luminogen shows outstanding photothermal conversion ability and improved thermal stability compared to ICG. Notably, after the photothermal treatment of drug-resistant tumor cells by the NIR II luminogen, the antitumor efficiency of chemotherapeutic drugs, including paclitaxel, cis-platinum, and doxorubicin, was significantly enhanced. The mechanism exploration revealed that drug resistance-related proteins were remarkably reduced, making the cells more sensitive toward drugs. Thus, this strategy demonstrated a promising and reliable approach to reverse the drug resistance of tumor cells for efficient tumor inhibition in the clinic.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Luminescence and Fluorescent Materials · Photodynamic Therapy Research Studies

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

State Key Laboratory of Luminescent Materials and Devices, Guangdong Provincial Key Laboratory of Luminescence from Molecular Aggregates, South China University of Technology, Guangzhou 510640, China

Molecular Aggregates, Center for Aggregation-Induced Emission, South China University of Technology, Guangzhou 510640, China

Department of Urology, The First Affiliated Hospital of Soochow University, Suzhou 215006, Jiangsu, China

Department of Gynecology, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou 510006, China

School of Chemistry and Chemical Engineering, University of South China, Hengyang 421001, China

School of Science and Engineering, Shenzhen Institute of Aggregate Science and Technology, The Chinese University of Hong Kong, henzhen (CUHK-Shenzhen), Shenzhen 518172, Guangdong, China

Hong Kong Branch of Chinese National Engineering Research Center for Tissue Restoration and Reconstruction, The Hong Kong University of Science and Technology, Kowloon 999077, Hong Kong, China

Funding

Special Project for Research and Development in Key areas of Guangdong Province · Guangdong Provincial Key Laboratory of Luminescence from Molecular Aggregates, South China University of Technology · Innovation and Technology Commission · Fundamental Research Funds for the Central Universities · National Natural Science Foundation of China

References (44)

Show source-provided references
1. 10.1038/nrc359910.1038/nrc3599 ↗
2. 10.1155/2021/383404010.1155/2021/3834040 ↗
3. 10.3389/fphar.2020.0089810.3389/fphar.2020.00898 ↗
4. 10.1158/1538-7445.AM2024-587010.1158/1538-7445.AM2024-5870 ↗
5. 10.1016/j.biomaterials.2020.12064910.1016/j.biomaterials.2020.120649 ↗
6. 10.1002/smll.20180078510.1002/smll.201800785 ↗
7. 10.1021/acsami.7b0387710.1021/acsami.7b03877 ↗
8. 10.1002/anie.20180945210.1002/anie.201809452 ↗
9. 10.1016/j.ejps.2018.04.02610.1016/j.ejps.2018.04.026 ↗
10. 10.3390/molecules2403056110.3390/molecules24030561 ↗
11. 10.3390/cancers1409234110.3390/cancers14092341 ↗
12. 10.1002/agt2.51410.1002/agt2.514 ↗
13. 10.1021/acs.chemrev.7b0025810.1021/acs.chemrev.7b00258 ↗
14. 10.1021/acs.biomac.1c0151610.1021/acs.biomac.1c01516 ↗
15. 10.1186/s12951-022-01679-010.1186/s12951-022-01679-0 ↗
16. 10.1021/acsnano.1c0157710.1021/acsnano.1c01577 ↗
17. 10.1002/smll.20200105910.1002/smll.202001059 ↗
18. 10.1002/anie.20180760210.1002/anie.201807602 ↗
19. 10.1002/anie.20210783610.1002/anie.202107836 ↗
20. 10.1002/agt2.45810.1002/agt2.458 ↗
21. 10.1021/acsnano.9b1014410.1021/acsnano.9b10144 ↗
22. 10.1002/adma.20210599910.1002/adma.202105999 ↗
23. 10.1002/adma.20230023210.1002/adma.202300232 ↗
24. 10.1039/D1BM00576F10.1039/D1BM00576F ↗
25. 10.1002/adfm.20210127810.1002/adfm.202101278 ↗
26. 10.1021/acsnano.5b0509710.1021/acsnano.5b05097 ↗
27. 10.1021/acsabm.8b0079310.1021/acsabm.8b00793 ↗
28. 10.1021/acs.molpharmaceut.8b0132110.1021/acs.molpharmaceut.8b01321 ↗
29. 10.1016/j.bioactmat.2021.10.04510.1016/j.bioactmat.2021.10.045 ↗
30. 10.1002/adma.20140218310.1002/adma.201402183 ↗
31. 10.1002/adma.20210814610.1002/adma.202108146 ↗
32. 10.1002/adom.20230116610.1002/adom.202301166 ↗
33. 10.1002/adma.20190785510.1002/adma.201907855 ↗
34. 10.1002/adma.20210650010.1002/adma.202106500 ↗
35. 10.1002/anie.20220721310.1002/anie.202207213 ↗
36. 10.1021/acsami.4c0225410.1021/acsami.4c02254 ↗
37. 10.1039/D1NR04227K10.1039/D1NR04227K ↗
38. 10.1002/adma.20200114610.1002/adma.202001146 ↗
39. 10.1021/jacs.0c0719310.1021/jacs.0c07193 ↗
40. 10.1021/jacs.2c0653810.1021/jacs.2c06538 ↗
41. 10.1021/acsnano.0c0276710.1021/acsnano.0c02767 ↗
42. 10.1016/j.ccr.2022.21456410.1016/j.ccr.2022.214564 ↗
43. 10.1016/j.dyepig.2013.08.00610.1016/j.dyepig.2013.08.006 ↗
44. 10.1002/adma.20160070610.1002/adma.201600706 ↗